First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review

This publication is a case report and literature review focusing on a 25-year-old man with ulcerative colitis treated with vedolizumab. The authors synthesize findings regarding a specific adverse event following intravenous administration of the medication in a single case setting. The study type is explicitly defined as a case report and literature review.

The primary outcome observed was recall urticaria, characterized by acute pruritic wheals localized exclusively to prior subcutaneous injection sites. The eruption resolved spontaneously within 24 h, and no systemic symptoms were reported. Despite the reaction, vedolizumab therapy was continued without discontinuation. Follow-up duration was recorded as 24 h.

The authors note that clinical features and underlying mechanisms remain poorly defined. They caution against inferring causality beyond the case report and literature review or generalizing findings to other populations or drugs. Safety data regarding serious adverse events and discontinuations were not reported in the source. Additional limitations include the inability to assume systemic safety based on one case.

Recall urticaria should be recognized as a site-specific hypersensitivity reaction distinct from systemic drug allergy. This case represents the first report of vedolizumab-associated recall urticaria, highlighting the need for vigilance without assuming systemic safety based on one case. Clinicians are advised to recognize this specific reaction type.